Evidence map›Paper›PMID 30107391›Full record

ArticleCardiovascular research2019

Y-27632 preconditioning enhances transplantation of human-induced pluripotent stem cell-derived cardiomyocytes in myocardial infarction mice.

Meng Zhao, Chengming Fan, Patrick J Ernst, Yawen Tang, Hanxi Zhu, Saidulu Mattapally, Yasin Oduk, Anton V Borovjagin, Lufang Zhou, Jianyi Zhang and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Meng ZhaoDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.
Chengming FanDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Patrick J ErnstDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Yawen TangDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Hanxi ZhuDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Saidulu MattapallyDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Yasin OdukDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Anton V BorovjaginDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Lufang ZhouDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Jianyi ZhangDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Wuqiang ZhuDepartment of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
University of Alabama at Birmingham · US

Funding

Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
Supplement of HL131017: Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytesR01HL131017 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SERPOOSHAN, VAHID, ZHANG, JIANYI · 2016 to 2025
$5.8M
Endogenous and exogenous mechanisms that promote myocardial remuscularization in post infarction LV remodelingR01HL114120 · NHLBI · UNIVERSITY OF MINNESOTA · PI ZHANG, JIANYI · 2012 to 2021
$5.6M
Stem Cells For Myocardial Repair: A Large Bore Magnet StudyR01HL095077 · NHLBI · UNIVERSITY OF MINNESOTA · PI ZHANG, JIANYI · 2009 to 2017
$3.8M
Mesenchymal Stem Cell Exosome in Efferocytosis of Apoptotic Cardiomyocytes and Repair after Myocardial IschemiaR01HL138023 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRISHNAMURTHY, PRASANNA, ZHANG, JIANYI · 2018 to 2021
$2.6M
Mitochondria-SR Redox Signaling and Ca2+ Handling in Healthy and Failing HeartsR01HL121206 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, LUFANG · 2015 to 2019
$1.8M
A Novel Optogenetic Tool for Precise Mitochondrial ControlR21HL127599 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, LUFANG · 2016 to 2017
$405k
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR56HL142627 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHU, WUQIANG · 2018 to 2018
$371k
NHLBI NIH HHS R01 HL095077NHLBI NIH HHS R01 HL114120NHLBI NIH HHS R01 HL121206NHLBI NIH HHS R01 HL131017NHLBI NIH HHS R01 HL138023NHLBI NIH HHS R21 HL127599NHLBI NIH HHS R56 HL142627NHLBI NIH HHS U01 HL134764
6 · The paper itself

Abstract

Aims: The effectiveness of cell-based treatments for regenerative myocardial therapy is limited by low rates of cell engraftment. Y-27632 inhibits Rho-associated protein kinase (ROCK), which regulates the cytoskeletal changes associated with cell adhesion, and has been used to protect cultured cells during their passaging. Here, we investigated whether preconditioning of cardiomyocytes, derived from human-induced pluripotent stem cells (hiPSC-CM), with Y-27632 improves their survival and engraftment in a murine model of acute myocardial infarction (MI). Methods and results: After MI induction, mice were subjected to intramyocardial injections of phosphate-buffered saline, hiPSC-CM cultured under standard conditions (hiPSC-CM-RI), or Y-27632-preconditioned hiPSC-CM (hiPSC-CM+RI). The resulting engraftment rate calculated 4 weeks after implantation was significantly higher and the abundance of apoptotic transplanted cells was significantly lower in hiPSC-CM+RI recipients than in hiPSC-CM-RI animals. In cultured hiPSC-CM, Y-27632-preconditioning reversibly reduced contractile activity and the expression of troponin genes, while increasing their attachment to an underlying mouse cardiomyocyte (HL1) monolayer. Y-27632 preconditioning also increased the expression of N-cadherin and integrin ß1, the two cell junction proteins. hiPSC-CM+RI were also larger in cell area with greater cytoskeletal alignment and a more rod-like shape than hiPSC-CM-RI, both after transplantation (in vivo) and in culture. The effects of Y-27632 preconditioning on contractile activity and morphology of hiPSC-CMs in culture, as well as on their engraftment rate and apoptotic death in MI mouse grafts, could be recapitulated by hiPSC-CM treatment with the L-type calcium-channel blocker verapamil. Conclusion: Preconditioning with the ROCK inhibitor Y-27632 increased the engraftment of transplanted hiPSC-CM in a murine MI model, while reversibly impairing hiPSC-CM contractility and promoting adhesion.

Indexed as

Cell DifferentiationAmidesAnimalsApoptosisCell AdhesionCells, CulturedCell SurvivalDisease Models, AnimalGraft SurvivalHumansInduced Pluripotent Stem CellsMice, Inbred NODMice, SCIDMyocardial ContractionMyocardial InfarctionMyocardiumAmidesProtein Kinase InhibitorsPyridinesrho-Associated KinasesY 27632

Identifiers

PMID30107391
PMCPMC6341224
OpenAlexW2887238772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.